Bisphosphonates Target B Cells to Enhance Humoral Immune Responses

Elena Tonti, Nereida JiménezdeOya, Gabriele Galliverti, E. Ashley Moseman, Pietro DiLucia, Angelo Amabile, Stefano Sammicheli, Marco DeGiovanni, Laura Sironi, Nicolas Chevrier, Giovanni Sitia, Luigi Gennari, LucaG Guidotti, UlrichH VonAndrian, Matteo Iannacone

Research output: Contribution to journalArticlepeer-review


Bisphosphonates are a class of drugs that are widely used to inhibit loss of bone mass in patients. We show here that the administration of clinically relevant doses of bisphosphonates in mice increases antibody responses to live and inactive viruses, proteins, haptens, and existing commercial vaccine formulations. Bisphosphonates exert this adjuvant-like activity in the absence of CD4+ and γδ Tcells, neutrophils, or dendritic cells, and their effect does not rely on local macrophage depletion, Toll-like receptor signaling, or the inflammasome. Rather, bisphosphonates target directly B cells and enhance B cell expansion and antibody production upon antigen encounter. These data establish bisphosphonates as an additional class of adjuvants that boost humoral immune responses

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalCell Reports
Issue number2
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Bisphosphonates Target B Cells to Enhance Humoral Immune Responses'. Together they form a unique fingerprint.

Cite this